Hughes-Stovin Syndrome: A Case Report of a 24-Year-Old Male with Pulmonary Aneurysms and Deep Vein Thrombosis

Despite the inherent risks associated with anticoagulation in HSS, the decision was made to resume apixaban due to the patient's significant thrombotic burden and stable PAAs, alongside continued immunosuppression and close monitoring. This case underscores the necessity of individualized treatment in HSS, balancing thrombotic versus hemorrhagic risk in the absence of definitive guidelines. Further research is crucial to establish evidence-based strategies for managing anticoagulation in this complex patient population.